PN summer web series kicks off in July! Learn more

Phase 1/2 Open-label Dose-escalation Study of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients with Painful Diabetic Peripheral Neuropathy

A team of researchers from the Department of Neurology, Northwestern University, reported on Phase 1/2 results of a study to evaluate the safety and preliminary efficacy of intramuscular injections of plasmid DNA (VM202) expressing two isoforms of hepatocyte growth factor (HGF) in patients with painful diabetic peripheral neuropathy (PDPN). Initial results are that VM202 treatment appeared to be safe, well tolerated, and sufficient to provide long-term symptomatic relief and improvement in th equality of life for patients with PDPN.  READ MORE

Source: Molecular Therapy